SWOT analysis of Bayer Company

The company wishes to gain maximum profit and ensure that they become the best company that supplies Aspirin to patients in different parts of the country. To achieve this, the company plans to manufacture the popular brands of Aspirin which is competitive drug in the drug market (Jeffreys, 2008). To be able to sell this competitive brand of Aspirin, the company will join the generic drug manufacturers association who have great influence in selling the Aspirin drug in different markets of the world. Strong business is a dream of every business and to be able to attain such dream, the Aspirin drug company will come up with policies and strategies that are aimed at ensuring that the business is growing daily and it is able to meet the growing demand from the customers (McSweeney et al., 2014).

The company will employ staff who are competent and have demonstrated integrity in their previous work (Savarese, 2017). The employees will be able to listen to customers and give a good response to them. The employees in the production areas will ensure that the drugs produced are of high quality. By doing so, they will be able to grow both the local and international markets. The company uses natural sources of drugs during manufacturing and will be doing awareness to let the public know that using natural drugs can help in solving their health problems. The pricing of the Aspirin drugs will be done based on what is available in the local and international market so that they can marge and not to be outdone by other similar drugs (Schoonveld, 2015).

The company will ensure that they produce drugs that meets the quality and assurance standards of the government and drug producer’s regulation authority(Gray et al., 2015). Complying with production regulations will ensure that they have the compliance certificate and the drugs will not be harmful to the patients and hence reducing lawsuits. The company will ensure that they maintain their patent policy (Epstein, 2005) and this will reduce counterfeit production of similar drugs by other companies. The price will also be a competitive one and will meet what it is available in the local and international market.


Epstein, R. A. (2005). Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale J. Health Pol’y L. & Ethics, 5, 741.

Gray, J. V, Anand, G., & Roth, A. V. (2015). The influence of ISO 9000 certification on process compliance. Production and Operations Management, 24(3), 369–382.

Jeffreys, D. (2008). Aspirin: the remarkable story of a wonder drug. Bloomsbury Publishing USA.

McSweeney, K., Nielsen, E. A., Taylor, M. J., Wrathall, D. J., Pearson, Z., Wang, O., & Plumb, S. T. (2014). Drug policy as conservation policy: narco-deforestation. Science, 343(6170), 489–490.

Savarese, C. (2017). The Chinese pharmaceutical market: an analysis of opportunities and challenges for Italian family firms. Università Ca’Foscari Venezia.

Schoonveld, M. E. (2015). The price of global health: drug pricing strategies to balance patient access and the funding of innovation. Gower Publishing, Ltd.